Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : ADVR:THE NEW COMPANY...WITH A NEW LIFE...AND A NEW MISSION -- Ignore unavailable to you. Want to Upgrade?

To: BARRY ALLEN who wrote (4199)	8/12/1999 9:51:00 PM
From: BARRY ALLEN	Read Replies (1) \| Respond to of 4891

As of June 30, 1999, we expended the following amounts for research and development in connection with the following ongoing studies which are being conducted abroad: o $50,000 has been advanced to DCT in connection with a study being conducted in Argentina by DCT on 65 patients to compare the results of treatment of AIDS patients using a three-drug cocktail and Reticulose versus AIDS patients taking a three-drug cocktail and a placebo, pursuant to an agreement entered in February 1998. o $85,000 has been advanced to DCT to cover the costs of a controlled study in 30 patients to determine the effectiveness of Reticulose for the treatment of rheumatoid arthritis in humans, pursuant to an agreement entered in May 1998. o $50,000 has been advanced to DCT to study the effects of Reticulose in inhibiting the mutation of the AIDS virus on patients in Argentina, pursuant to an agreement entered in July 1998. During 1999, we expect to spend approximately $1,000,000 on research and development related activities, including: o approximately $300,000 in the preparation of the IND; o approximately $325,000 in connection with laboratory research, equipment, supplies and electronics; o approximately $300,000 in overseas research of Reticulose; and o approximately $75,000 in preparing the manufacturing facility in the Bahamas for FDA inspection and in accordance with good manufacturing practices standards.